For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the introduction of Vyndamax and Tafamidis meglumine represents a significant change. These novel therapies protect the transthyretin protein, halting its damaging build-up and alleviating the severity o